Literature DB >> 20404121

In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center.

Michael J Zapor1, Melissa Barber, Amy Summers, George H Miller, Lee Ann Feeney, Lynn E Eberly, Glenn Wortmann.   

Abstract

We determined the in vitro MIC of arbekacin against 200 Acinetobacter isolates recovered from wounded soldiers. The median MIC was 2 microg/ml (range, 0.5 to > 64 microg/ml). A total of 97.5% of the isolates had arbekacin MICs of < 8 microg/ml and 86.5% had MICs of < or = 4 microg/ml. There was no association between the arbekacin MIC and susceptibility to 16 other antibiotics or the specimen source (P = 0.7239). Synergy testing suggested an enhanced effect of arbekacin-carbapenem combinations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20404121      PMCID: PMC2897312          DOI: 10.1128/AAC.01173-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

Review 1.  Aminoglycosides: activity and resistance.

Authors:  M P Mingeot-Leclercq; Y Glupczynski; P M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

2.  Synergy with aztreonam and arbekacin or tobramycin against Pseudomonas aeruginosa isolated from blood.

Authors:  Y Kobayashi; H Uchida; Y Kawakami
Journal:  J Antimicrob Chemother       Date:  1992-12       Impact factor: 5.790

3.  Emergence of multidrug resistance in bacteria and impact on antibiotic expenditure at a major army medical center caring for soldiers wounded in Iraq and Afghanistan.

Authors:  Michael J Zapor; Daniel Erwin; Goldina Erowele; Glenn Wortmann
Journal:  Infect Control Hosp Epidemiol       Date:  2008-07       Impact factor: 3.254

4.  New techniques for purifying large DNAs and studying their properties and packaging.

Authors:  D C Schwartz; W Saffran; J Welsh; R Haas; M Goldenberg; C R Cantor
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1983

5.  Comparison of netilmicin and gentamicin pharmacokinetics in humans.

Authors:  M Chung; R Costello; S Symchowicz
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

6.  Efficacy of ampicillin plus arbekacin in experimental rabbit endocarditis caused by an Enterococcus faecalis strain with high-level gentamicin resistance.

Authors:  V Kak; S M Donabedian; M J Zervos; R Kariyama; H Kumon; J W Chow
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

7.  In vitro antimicrobial activity of the aminoglycoside arbekacin tested against oxacillin-resistant Staphylococcus aureus isolated in Brazilian hospitals.

Authors:  J C Cordeiro; A O Reis; E A Miranda; H S Sader
Journal:  Braz J Infect Dis       Date:  2003-02-19       Impact factor: 1.949

8.  The most frequent aminoglycoside resistance mechanisms--changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups.

Authors:  G H Miller; F J Sabatelli; R S Hare; Y Glupczynski; P Mackey; D Shlaes; K Shimizu; K J Shaw
Journal:  Clin Infect Dis       Date:  1997-01       Impact factor: 9.079

9.  Synergy of arbekacin-based combinations against vancomycin hetero-intermediate Staphylococcus aureus.

Authors:  Ji Young Lee; Won Sup Oh; Kwan Soo Ko; Sang Taek Heo; Chi Sook Moon; Hyun Kyun Ki; Sungmin Kiem; Kyong Ran Peck; Jae Hoon Song
Journal:  J Korean Med Sci       Date:  2006-04       Impact factor: 2.153

10.  Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center.

Authors:  Joshua D Hartzell; Robert Neff; Julie Ake; Robin Howard; Stephen Olson; Kristopher Paolino; Mark Vishnepolsky; Amy Weintrob; Glenn Wortmann
Journal:  Clin Infect Dis       Date:  2009-06-15       Impact factor: 9.079

View more
  7 in total

1.  Determination of MIC distribution of arbekacin, cefminox, fosfomycin, biapenem and other antibiotics against gram-negative clinical isolates in South India: a prospective study.

Authors:  Sangeetha Rajenderan; Veeraraghavan Balaji; Shalini Anandan; Rani Diana Sahni; Giannoula S Tansarli; Matthew E Falagas
Journal:  PLoS One       Date:  2014-07-28       Impact factor: 3.240

2.  Detection of New Delhi metallo-β-lactamase (encoded by blaNDM-1) in Acinetobacter schindleri during routine surveillance.

Authors:  Patrick McGann; Michael Milillo; Robert J Clifford; Erik Snesrud; Lindsay Stevenson; Michael G Backlund; Helen B Viscount; Reyes Quintero; Yoon I Kwak; Michael J Zapor; Paige E Waterman; Emil P Lesho
Journal:  J Clin Microbiol       Date:  2013-04-03       Impact factor: 5.948

3.  Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia.

Authors:  Helio S Sader; Paul R Rhomberg; David J Farrell; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2015-03-23       Impact factor: 5.191

4.  Detecting 16S rRNA Methyltransferases in Enterobacteriaceae by Use of Arbekacin.

Authors:  Patrick McGann; Sarah Chahine; Darius Okafor; Ana C Ong; Rosslyn Maybank; Yoon I Kwak; Kerry Wilson; Michael Zapor; Emil Lesho; Mary Hinkle
Journal:  J Clin Microbiol       Date:  2015-11-04       Impact factor: 5.948

Review 5.  Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens.

Authors:  Tetsuya Matsumoto
Journal:  Clin Pharmacol       Date:  2014-09-26

Review 6.  Clinical Usefulness of Arbekacin.

Authors:  Jae Hoon Lee; Chang-Seop Lee
Journal:  Infect Chemother       Date:  2016-03-31

7.  Mutational and acquired carbapenem resistance mechanisms in multidrug resistant Pseudomonas aeruginosa clinical isolates from Recife, Brazil.

Authors:  Felipe Lira de Sá Cavalcanti; Cristina Rodríguez Mirones; Elena Román Paucar; Laura Álvarez Montes; Tereza Cristina Leal-Balbino; Marcia Maria Camargo de Morais; Luis Martínez-Martínez; Alain Antonio Ocampo-Sosa
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-12-15       Impact factor: 2.743

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.